{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:57:31Z","timestamp":1781690251673,"version":"3.54.5"},"reference-count":7,"publisher":"Norwegian Medical Association","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.25.0655","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T13:45:14Z","timestamp":1763387114000},"source":"Crossref","is-referenced-by-count":0,"title":["Botox for overactive bladder \u2013 a perfect treatment?"],"prefix":"10.4045","volume":"145","author":[{"given":"Henriette Veiby","family":"Holm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref=1","unstructured":"Weckx\u00a0F, Tutolo\u00a0M, De Ridder\u00a0D et al. The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol 2016; 5: 63\u201371. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26904413&dopt=Abstract"},{"key":"ref=2","unstructured":"Myhr\u00a0SS, Schi\u00f8tz\u00a0HA. Cystoskopisk injeksjon av botulinumtoksin for overaktiv bl\u00e6re med lekkasje. Tidsskr Nor Legeforen 2025; 145. doi: 10.4045\/tidsskr.25.0247. Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.25.0247"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Serati\u00a0M, Cantaluppi\u00a0S, Coluccia\u00a0AC et al. Is urodynamic evaluation able to change and improve the management of women with idiopathic overactive bladder? Minerva Urol Nephrol 2021; 73: 823\u201330. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32573171&dopt=Abstract","DOI":"10.23736\/S0393-2249.20.03801-1"},{"key":"ref=4","unstructured":"Drake\u00a0MJ. Fundamentals of terminology in lower urinary tract function. Neurourol Urodyn 2018; 37 (S6): S13\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30614063&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fnau.23768"},{"key":"ref=5","unstructured":"Guidelines EAU. Management of Non-neurogenic Male LUTS. https:\/\/uroweb.org\/guidelines\/management-of-non-neurogenic-male-luts\/chapter\/epidemiology-aetiology-and-pathophysiology Lest 1.11.2025."},{"key":"ref=6","unstructured":"Guidelines EAU. Non-neurogenic Female LUTS. https:\/\/uroweb.org\/guidelines\/non-neurogenic-female-luts Lest 1.11.2025."},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Franco\u00a0I, Schwartz\u00a0M, Cline\u00a0K et al. Predicting Elevated Postvoid Residual Urine Volume Following OnabotulinumtoxinA Treatment for Overactive Bladder: A Pilot Study. Low Urin Tract Symptoms 2025; 17: e70004. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39800349&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fluts.70004","DOI":"10.1111\/luts.70004"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Botox for overaktiv bl\u00e6re \u2013 en perfekt behandling?"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:32:35Z","timestamp":1781688755000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2025\/11\/invitert-kommentar\/botox-overaktiv-blaere-en-perfekt-behandling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":7,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.25.0655","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}